

**Contacts:**

Silence Therapeutics  
Phil Haworth  
(650) 855-1514  
[p.haworth@silence-therapeutics.com](mailto:p.haworth@silence-therapeutics.com)

Vida Communication (on behalf of Silence)  
Tim Brons (media)  
(415) 675-7400  
[tbrons@vidacommunication.com](mailto:tbrons@vidacommunication.com)

Stephanie Diaz (investors)  
(415) 675-7400  
[sdiaz@vidacommunication.com](mailto:sdiaz@vidacommunication.com)

**FOR IMMEDIATE RELEASE****Silence Therapeutics to Present at 12<sup>th</sup> Annual BIO CEO & Investor Conference**

**London and Palo Alto, CA, February 5, 2010** – Silence Therapeutics plc (AIM: SLN) today announced that Philip Haworth, Ph.D., chief executive officer, will deliver a corporate overview and business update at the 12<sup>th</sup> Annual BIO CEO & Investor Conference. The conference will be held February 8-9, 2010 at the Waldorf-Astoria Hotel in New York City.

Silence's presentation will take place at 11:00 a.m. Eastern on Monday, February 8, 2010. The corporate update provided by Dr. Haworth will include an overview of the company's recent merger with Intradigm Corporation, as well as details on the company's expanded RNA interference (RNAi) therapeutic platform and pipeline.

To access a live audio webcast of the presentation, please log on through a link located on the Presentations page of the Investor Relations section of Silence's website at [http://www.silence-therapeutics.com/index.php?option=com\\_content&task=view&id=88&Itemid=88](http://www.silence-therapeutics.com/index.php?option=com_content&task=view&id=88&Itemid=88)

**About Silence Therapeutics plc ([www.silence-therapeutics.com](http://www.silence-therapeutics.com))**

Silence Therapeutics plc (AIM: SLN) is a leading global biotechnology company dedicated to the discovery, development and delivery of targeted, systemic RNA interference (RNAi) therapeutics for the treatment of serious diseases. The company possesses multiple proprietary siRNA delivery technology platforms including AtuPLEX, a system that enables the functional delivery of siRNA molecules to targeted diseased tissues and cells, while increasing their bioavailability and intracellular uptake. A second, complementary delivery technology known as PolyTran™ offers safe and effective systemic administration using a library of novel peptide-based biodegradable polycationic polymers. Additionally, the company has a platform of novel short interfering RNA (siRNA) molecules, AtuRNAi, which provide a number of advantages over conventional siRNA molecules, including increased stability against nuclease degradation. Silence's unique RNAi assets also include structural features for a next generation of RNAi molecules and additional proprietary siRNA sequences against more than 50 highly valued oncology and other disease targets.

Silence has built a strong and diverse intellectual property portfolio covering all essential areas of RNAi therapeutic development including multiple proprietary siRNA delivery technologies, potent siRNA sequences and key siRNA structural and chemical features, as well as specific high-value disease targets. This portfolio includes an exclusive license to the Zamore patent family from the University of Massachusetts, which covers broad structural features of siRNA design for more potent next generation siRNA sequences.

Silence Therapeutics is headquartered in London, UK, with research and development operations in Berlin and Palo Alto, CA.

### **Forward-Looking Statements**

This press release includes forward-looking statements that are subject to risks, uncertainties and other factors. These risks and uncertainties could cause actual results to differ materially from those referred to in the forward-looking statements. All forward-looking statements are based on information currently available to Silence Therapeutics and Silence Therapeutics assumes no obligation to update any such forward-looking statements.

###